7例鼻腔鼻窦神经内分泌癌的治疗和预后  

Treatment and prognosis of 7 cases with sinonasal neuroendocrine carcinoma

作　　者：问静[1] 吴建峰[1] 严鹏伟[1] 郭文杰[1] 黄生富[1] 姜雪松[1] 何侠[1] 

机构地区：[1]江苏省肿瘤医院放疗科,南京210009

出　　处：《临床肿瘤学杂志》2016年第1期78-81,共4页Chinese Clinical Oncology

摘　　要：目的 探讨鼻腔鼻窦神经内分泌癌（SNEC）的治疗方式及预后。方法 对2012年5月至2014年7月收治的7例SNEC患者的临床资料进行回顾性分析。7例患者均为男性，年龄范围39～61岁，就诊主要症状为鼻塞、头痛及面部肿胀疼痛等。临床分期：ⅣA期3例，ⅣB期3例，1例不详。1例行新辅助化疗＋手术，1例行术前化放疗＋手术，5例行根治性放疗＋化疗。结果 7例患者放疗结束时疗效评价均为PR，2例在随访期间获CR。7例患者的随访时间为10～56个月，1例因远处转移死亡，6例随访期间均存活。主要不良反应为口腔黏膜炎、骨髓抑制和转氨酶升高。结论 SNEC临床少见，临床表现不典型，恶性程度高，采取以放疗为主的综合治疗是改善局部晚期患者预后的重要途径。Objective To explore the treatment and prognosis of sinonasal neuroendocrine carcinoma （SNEC）. Methods A retrospective analysis of 7 patients with SNEC from May 2012 to July 2014 was performed. All the patients were male and age from 39 to 61. The main symptoms were nasal obstruction, headache, and facial swelling and pain. Three patients were in IVA stage, three were in IVB stage and one unknown. One patient underwent preoperative chemotherapy and surgery, one with preoperative chemoradiotherapy and surgery, and five patients received radical radiotherapy in combination with chemotherapy. Results Partial remission was observed in all 7 patients after treatment and complete remission was observed in 2 patients during follow-up. The follow-up ranged from 10-56 months. One patient died of distant metastasis, and the remaining 6 patients were still alive in follow-up. The side effects included oral mucositis, myelosuppression and transaminase elevation. Conclusion SNEC is rare and highly malignant in clinic without typical clinical presentation. Comprehensive treatment based on radiotherapy may improve prognosis of patients with local advance.

关 键 词：鼻腔鼻窦肿瘤 神经内分泌癌 综合治疗 

分 类 号：R739.6[医药卫生—肿瘤]